Despite low volatility in the domestic stock markets over the past few months, investors are expected to tread cautiously ...

Domestic brokerage Nuvama Institutional Equities warned that Nifty 50's decline is due to weak earnings and high valuations, ...

Nuvama is of the view that the Zydus Life's latest deal would be dilutive to the company's Earnings Per Share (EPS) by 1% to ...

While the central bank's easing measures may provide short-term relief, global uncertainties—such as a US growth slowdown and ...

Given the persistent selling by global funds, Nifty recorded five consecutive months of selling - the first time in three ...

India’s earnings are reconciling with not just weak top-line growth, but also its EM peers. High valuation only added to the ...

Nuvama cuts Zydus Lifesciences target by 16%, citing weak synergy with Amplitude acquisition. Read more about the financial outlook now!

Nuvama slashes BSE's target price, citing reduced volumes from NSE changes and SEBI's derivative rules. Explore the ...

Brokerages deemed Zydus Life's acquisition of Amplitude Surgical as expensive, with subpar synergies that has triggered ...

Citi's picks in India's asset management companies are 360 One, Nuvama and Prudent. While Aditya Birla Sun Life AMC Ltd's ...

Shares of Zee Entertainment rose on Friday after brokerage house Nuvama maintained a 'buy' rating with a target price of Rs ...

Nuvama Institutional Equities has kept its 'Buy' rating on BSE Ltd intact amid what it called the futures and options (F&O) expiry war with peer NSE. The brokerage has, however, cut its target ...